ObjectiveWe undertook a non-targeted lipidomics analysis of post-mortem cerebrospinal
fluid (CSF), frontal cortex grey matter, and subjacent white matter to define potential …

Background: The plasma fraction GRF6019 shows multiple benefits on brain aging in mice,
including enhanced cognition, neurogenesis, and synaptic density, as well as reduced …

Introduction This phase 2b/3 trial examined the effects of plasma exchange (PE) in patients
with mild‐to‐moderate Alzheimer's disease (AD). Methods Three hundred forty‐seven …

Background: Choline alphoscerate (alpha glyceryl phosphorylcholine, α-GPC) is a choline-
containing phospholipid used as a medicine or nutraceutical to improve cognitive function …

Abstract Hypothesis We hypothesized that Lomecel‐B, an allogeneic medicinal signaling
cell (MSC) therapeutic candidate for Alzheimer's disease (AD), is safe and potentially …

Alzheimer's disease (AD) is the most common form of neurodegenerative dementia and
there is no cure to date. Biomarkers in cerebrospinal fluid (CSF) are already included in the …

Introduction We report previously unpublished, early pilot studies performed with a brain-
health food supplement containing a proprietary blend of 100 mg phosphatidylserine (PS) …

As neuroinflammation is an early event in the pathogenesis of Alzheimer's disease, new
selective antiinflammatory drugs could lead to promising preventive strategies. We …

Abstract Objective The effects of (−)‐phenserine (phenserine) and placebo/donepezil
treatment on regional cerebral metabolic rate for glucose (rCMRglc) and brain amyloid load …

Alzheimer's disease (AD) is a progressive, neurodegenerative disease, characterised by
decline of memory, cognitive function and changes in behaviour. Generic markers of lipid …